Little Help from Lucentis for Vitreous Hemorrhage (CME/CE)
(MedPage Today) -- Patients with vitreous hemorrhage related to diabetic retinopathy derived minimal short-term benefit from treatment with the angiogenesis inhibitor ranibizumab (Lucentis), results of a randomized trial showed. (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - February 5, 2013 Category: Opthalmology Source Type: news
Little Help from Lucentis for Diabetic Eyes (CME/CE)
(MedPage Today) -- Patients with vitreous hemorrhage related to diabetic retinopathy derived minimal short-term benefit from treatment with the angiogenesis inhibitor ranibizumab (Lucentis), results of a randomized trial showed. (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - February 1, 2013 Category: Opthalmology Source Type: news
Ranibizumab Fails to Beat Saline in Avoiding VitrectomyRanibizumab Fails to Beat Saline in Avoiding Vitrectomy
Patients with vitreous hemorrhage from proliferative diabetic retinopathy who received intravitreal injections of ranibizumab or saline had about the same rates of vitrectomy by 16 weeks. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
NETAG issues appraisal and recommendation on aflibercept for AMD
Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) has undertaken an appraisal of aflibercept (Eylea®) within its licensed indication for the management of neovascular (wet) age-related macular degeneration (AMD). The Group recommends its use, within its licensed indication, for the treatment of newly diagnosed and untreated wet AMD. It does not however recommend its use for the same episode of AMD refractory to treatment with other biological therapies such as ranibizumab. This recommendation is contingent on a maximum cost per aflibercept dose as stated in the ...
Source: NeLM - Drug Specific Reviews - January 21, 2013 Category: Drugs & Pharmacology Source Type: news
NICE makes u-turn decision on Lucentis
A UK health watchdog has recommended the use of Lucentis for the treatment of visual impairment caused by diabetic macular oedema (DMO) after manufacturer Novartis dropped the price of the drug. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 7, 2013 Category: Pharmaceuticals Source Type: news
